Cargando…
Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies desi...
Autores principales: | Kellner, Christian, Peipp, Matthias, Gramatzki, Martin, Schrappe, Martin, Schewe, Denis M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136853/ https://www.ncbi.nlm.nih.gov/pubmed/30221037 http://dx.doi.org/10.1080/2162402X.2018.1448331 |
Ejemplares similares
-
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020) -
Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype
por: Kellner, Christian, et al.
Publicado: (2013) -
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
por: Lenk, Lennart, et al.
Publicado: (2022) -
Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo
por: Winterberg, Dorothee, et al.
Publicado: (2021) -
Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)